TrialCompass TCL
Back to results
RecruitingPriority 4 · Lower priorityNCT02848274

ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome

ClinicalTrials.gov

Plain-language summary

This trial is studying a new treatment for people with cutaneous T-cell lymphoma (skin lymphoma). The study measures how well this treatment works and monitors for side effects. It is available at 7 US locations across multiple states.

Who can join (key eligibility)

  • See full trial listing for complete eligibility

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Drugs / treatments
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome

NCT02848274

Phase: | Status: Recruiting | Priority: Lower

Plain-language summary

This trial is studying a new treatment for people with cutaneous T-cell lymphoma (skin lymphoma). The study measures how well this treatment works and monitors for side effects. It is available at 7 US locations across multiple states.

Who can join

  • See full trial listing for complete eligibility

What's being tested

Drugs / treatments:

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, blind

Enrollment target: 2000 patients

Primary endpoint: Overall survival (OS)

Ages: — to —

Start date: 2016-10 | Est. completion: 2027-03

Locations

7 US sites · 13 total

California, Iowa, New Jersey, Pennsylvania, Texas, Utah

Contact

Tatiana Neal | tatianan@stanford.edu | 650-709-7838

Sponsor: Stanford University (OTHER)

Tags

CTCL · any

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT02848274

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.